Literature DB >> 9220046

Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.

J W Grunden1, K A Fisher.   

Abstract

OBJECTIVE: To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin. CASE SUMMARIES: In each case, the patients were treated over 5 years with lovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic. Following intravenous hydration and administration of bicarbonate, the patients' condition resolved without permanent' sequelae. DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including lovastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin-induced rhabdomyolysis. To our knowledge, these cases are the first published reports of lovastatin-induced rhabdomyolysis associated with azithromycin and clarithromycin.
CONCLUSIONS: The risk of drug-induced rhabdomyolysis due to the potential interaction between lovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220046     DOI: 10.1177/106002809703100710

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  13 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease.

Authors:  J I Kuper; M D'Aprile
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.

Authors:  Tuire Tirkkonen; Anna Ryynänen; Tero Vahlberg; Kerttu Irjala; Timo Klaukka; Risto Huupponen; Kari Laine
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  [Authors reply].

Authors:  J M Alvarez Gutiérrez; J D López-Torres Hidalgo; E M García Ruiz; F Naharro De Mora; P Galdón Blesa
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

5.  [Pharmacological interactions of statins].

Authors:  J M Alvarez Gutiérrez; J D López-Torres Hidalgo; P Galdón Blesa; E M García Ruiz; F Naharro de Mora
Journal:  Aten Primaria       Date:  2003-03-15       Impact factor: 1.137

Review 6.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 8.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

9.  Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

Authors:  Johanna Strandell; Andrew Bate; Staffan Hägg; I Ralph Edwards
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

10.  Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin.

Authors:  Gaurav Alreja; Saqib Inayatullah; Saurabh Goel; Gregory Braden
Journal:  J Cardiovasc Dis Res       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.